ERBB2 and breast carcinoma: In 2020, the FDA approved neratinib in combination with capecitabine (N + C) for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens in the metastatic setting [9].